Remicade and Xarelto woes—and Trump pricing threats—haven't stopped Johnson & Johnson hiking its 2018 forecast
admin 17th April 2018 Uncategorised 0Johnson & Johnson faces a litany of problems, ranging from biosimilar competition to its blockbuster Remicade to a sagging baby-care product line beset by lawsuits claiming its famous talcum powder causes cancer. But executives are clearly not concerned—at least not about J&J’s short-term fortunes.
More: Remicade and Xarelto woes—and Trump pricing threats—haven't stopped Johnson & Johnson hiking its 2018 forecast
Source: fierce